Thread
Peptides first sold for weight and blood sugar are being tested on sleep, kidneys, liver and the brain.
The open questionWhich organ benefits hold up in outcome trials, and which do not?
This thread collects the trials and label decisions that test peptide medicines on organs and conditions beyond body weight: kidneys, liver, sleep apnea, the heart and the brain. Some of these results led to new labels; others missed their goal. The spine below keeps both kinds in one line, in filing order, so a reader can see which claims held up in outcome trials and which did not.
FlashREGStart
Zepbound (tirzepatide) is now approved for moderate-to-severe obstructive sleep apnea in adults with obesity, alongside diet and exercise.
1st prescription drug approved to treat obstructive sleep apnea in adults with obesity
UrgentREG+1 mo
FDA approved a new indication for Ozempic (semaglutide) in type 2 diabetes with chronic kidney disease, based on the FLOW outcome trial.
24% lower risk of kidney failure, major kidney decline or death from kidney or heart causes
FlashREG+7 mo
FDA granted accelerated approval to Wegovy for adults with MASH (formerly NASH) and moderate to advanced liver fibrosis, without cirrhosis.
62.9% of treated patients saw liver inflammation resolve without fibrosis worsening, vs 34.3% on placebo
UrgentTRL+3 mo
EVOKE and EVOKE+ both missed their primary endpoint: no meaningful difference in cognitive and functional decline after two years.
0 of 2 phase 3 trials that met their main goal of slowing cognitive decline